Clinical Trial

Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis

Study acronym: PBMC-KOA
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The goal of this Phase II/III, double-blinded, multicenter clinical trial is to assess the clinical efficacy of autologous peripheral blood mononuclear cells (PBMCs) in the management of knee osteoarthritis (KOA). The main questions it aims to answer are: 1. To determine the safety of the PCP-PBMCs injection 2. To compare the long-term efficacy between PCP-PBMCs and methylprednisolone on pain relief and motor function restoration 3. To analyze improving quality of life after the PCP-PBMCs treatment.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-07-21
Trial Details
NCT Number NCT07703280
Lead Sponsor DuoGenic StemCells Corporation (DGSC)
Collaborators: National Taiwan University Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital, Chiayi, Kaoshiung Chang Gung Memorial Hospital
Conditions Knee Osteoarthritis
Enrollment 240 participants
Start Date 2026-09-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20